Placebo News and Research

RSS

Ritalin helps improve brain function in cocaine addiction

A single dose of a commonly-prescribed attention deficit hyperactivity disorder drug helps improve brain function in cocaine addiction, according to an imaging study conducted by researchers from the Icahn School of Medicine at Mount Sinai.

28 Jun 2013

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Sprout Pharmaceuticals, the Raleigh-based pharmaceutical company developing flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder in pre-menopausal women, confirmed today that the company has resubmitted the New Drug Application for flibanserin earlier this year and expects US Food and Drug Agency action before the end of 2013.

27 Jun 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase, in patients with advanced cancer.

26 Jun 2013

Vitamin D supplements lower blood pressure, improve moods in women with diabetes and depression

In women who have type 2 diabetes and show signs of depression, vitamin D supplements significantly lowered blood pressure and improved their moods, according to a pilot study at Loyola University Chicago Niehoff School of Nursing.

26 Jun 2013

AtheroNova starts AHRO-001 Phase 1 clinical trial for treatment of atherosclerosis

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers.

25 Jun 2013

Study shows risk of Guillain-Barre syndrome after vaccination is extremely low

Patients are not at increased risk of Guillain-Barr- syndrome in the six-week period after vaccination with any vaccine, including influenza, according to a Kaiser Permanente study published in Clinical Infectious Diseases.

25 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada.

24 Jun 2013

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

One of the largest clinical trials done in infants with congenital (present at birth) heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix-) to reduce shunt-related blood flow issues is not effective in the dose studied.

21 Jun 2013

Laughing gas is associated with increased risk for perioperative cardiac events

A clinical trial published in the July issue of Anesthesiology may shed some light on whether nitrous oxide ("laughing gas") causes an increased risk for cardiac events, including heart attacks after surgery, particularly among high-risk patients.

20 Jun 2013

Researchers launch clinical trial on stem cells to prevent amputations in end stage PAD

University Hospitals Case Medical Center clinical researchers have launched an innovative clinical trial, unique in its design, which will evaluate the ability of a patient's own stem cells to prevent leg amputations in end stage peripheral arterial disease (PAD).

20 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Loyola researcher to study role of Vitamin D in women with diabetes and depression

A Loyola University Chicago Niehoff School of Nursing researcher has received a four-year, $1.49 million grant to study whether Vitamin D can improve mood in women with diabetes who are depressed.

20 Jun 2013

Placebo News and Research

Ritalin helps improve brain function in cocaine addiction

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Eisai submits BELVIQ NDS with Health Canada

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Vitamin D supplements lower blood pressure, improve moods in women with diabetes and depression

AtheroNova starts AHRO-001 Phase 1 clinical trial for treatment of atherosclerosis

Study shows risk of Guillain-Barre syndrome after vaccination is extremely low

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

Laughing gas is associated with increased risk for perioperative cardiac events

Researchers launch clinical trial on stem cells to prevent amputations in end stage PAD

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Loyola researcher to study role of Vitamin D in women with diabetes and depression

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News